Celsee Launches Genesis System to Overcome Prior Limits of Single-cell Analysis
Ann Arbor, Mich. – October 25, 2018 – Celsee, Inc., today launched its first product, the Genesis system, designed to overcome the limitations of other tools for single-cell analysis. The Genesis system provides a robust, scalable, and flexible way for scientists to analyze and interpret cellular behavior and collect critical cell-based information that was previously undetectable. Initial applications include proteogenomics; immune monitoring as an alternative to flow cytometry; and expansion and scale of next-generation sequencing library preparation.
The importance of analyzing individual cells, rather than relying on bulk populations or tissue-based assessment, is now well understood in fields such as oncology, stem cell research, and immunology. For many medical conditions, the cell is the fundamental unit from which to determine disease onset, progression, and potential treatment matches. Access to the genomic or proteomic content in a cell, as well as to cell cycle or state, can provide critical information that can drive a more complete understanding of disease progression and potential response to treatment. In order to obtain the most meaningful information, scientists need intact and viable cells that have not been damaged by harsh cellular analysis and manipulation processes.
“Commonly used single-cell analysis technologies lack the capture efficiency, cell viability, and reproducibility needed to achieve the scalability required for widespread use in research and clinical settings,” said John Stark, Chief Executive Officer of Celsee. “The Celsee Genesis system overcomes these deficiencies and provides clinical-grade, single-cell analysis at scale. We are excited about the opportunities to improve the experimental process in emerging fields such as proteogenomics and understanding response to immunotherapies.”
The company’s patented technology uses a gentle, gravity-based method to capture and isolate individual cells while maintaining viability and structural integrity. The Celsee Genesis workflow achieves capture efficiencies of >70% and improved sensitivity versus other commonly used techniques for single-cell analysis. The open and flexible platform can be used directly with blood and tissue samples, offering a practical solution for understanding and monitoring cell-based diseases whether users are interested in studying an individual cell or millions from a single sample.
Celsee, Inc., a privately held company in the Ann Arbor, Michigan area, is breaking through the traditional barriers of single-cell analysis and delivering clinical-grade technology designed to support the life sciences revolution and precision medicine. Based on a gentle, gravity-induced, micro-well isolation technique, the patented technology forms the foundation for an elegant, scalable, and flexible single-cell analysis platform that makes more experiments feasible. Celsee’s first product, the Genesis system, enables scientists to analyze and interpret cellular behavior and collect previously inaccessible information for improved results in applications such as proteogenomics, next-generation sequencing, immune monitoring, and cell therapy. For more information, visit www.celsee.com.